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Your responsibility 
The recommendations in this guidance represent the view of NICE, arrived at after careful 
consideration of the evidence available. When exercising their judgement, health professionals are 
expected to take this guidance fully into account, alongside the individual needs, preferences and 
values of their patients. The application of the recommendations in this guidance are at the 
discretion of health professionals and their individual patients and do not override the 
responsibility of healthcare professionals to make decisions appropriate to the circumstances of 
the individual patient, in consultation with the patient and/or their carer or guardian. 
Commissioners and/or providers have a responsibility to provide the funding required to enable 
the guidance to be applied when individual health professionals and their patients wish to use it, in 
accordance with the NHS Constitution. They should do so in light of their duties to have due regard 
to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce 
health inequalities. 
Commissioners and providers have a responsibility to promote an environmentally sustainable 
health and care system and should assess and reduce the environmental impact of implementing 
NICE recommendations wherever possible. 
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This guidance replaces ESNM29. 
1 Guidance 
1.1 Nalmefene is recommended within its marketing authorisation, as an option for 
reducing alcohol consumption, for people with alcohol dependence: 
• who have a high drinking risk level (defined as alcohol consumption of more than 60 g 
per day for men and more than 40 g per day for women, according to the World Health 
Organization's drinking risk levels) without physical withdrawal symptoms and 
• who do not require immediate detoxification. 
The marketing authorisation states that nalmefene should: 
• only be prescribed in conjunction with continuous psychosocial support focused on 
treatment adherence and reducing alcohol consumption and 
• be initiated only in patients who continue to have a high drinking risk level 2 weeks 
after initial assessment. 
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2 The technology 
2.1 Nalmefene (Selincro, Lundbeck) is an opioid receptor modulator, which exhibits 
antagonist activity at the mu and delta opioid receptors, and partial agonist 
activity at the kappa opioid receptors. Nalmefene has a marketing authorisation 
in the UK for 'the reduction of alcohol consumption in adult patients with 
alcohol dependence who have a high drinking risk level without physical 
withdrawal symptoms and who do not require immediate detoxification'. The 
summary of product characteristics states that a high drinking risk level is 
defined as alcohol consumption of more than 60 g (7.5 units) per day for men 
and more than 40 g (5 units) per day for women, according to the World Health 
Organization's drinking risk levels. 
2.2 The marketing authorisation also states that 'nalmefene should only be 
prescribed in conjunction with continuous psychosocial support focused on 
treatment adherence and reducing alcohol consumption. It should only be 
started in patients who continue to have a high drinking risk level 2 weeks after 
initial assessment'. 
2.3 The summary of product characteristics lists the following adverse reactions for 
nalmefene: nausea, dizziness, insomnia and headaches. For full details of 
adverse reactions and contraindications, see the summary of product 
characteristics. 
2.4 Nalmefene is available as an 18 mg film-coated tablet and is priced at £42.42 for 
a pack of 14 tablets or £84.84 for a packet of 28 tablets (excluding VAT; 'British 
national formulary' [BNF], online April 2014). It is taken orally at a maximum 
dose of 1 tablet daily on an 'as-needed' basis. Costs may vary in different 
settings because of negotiated procurement discounts. 
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3 The company's submission 
The Appraisal Committee (section 7) considered evidence submitted by the company of nalmefene 
and a review of this submission by the Evidence Review Group (ERG; section 8). 
Clinical effectiveness 
Nalmefene compared with psychological intervention 
3.1 The company identified 3 randomised controlled trials (ESENSE1, ESENSE2 and 
SENSE) in adults with alcohol dependence, comparing 18 mg nalmefene (on an 
as-needed basis) plus psychosocial support with placebo plus psychosocial 
support. ESENSE1 (n=604) and ESENSE2 (n=718) were identical efficacy 
studies with a follow-up period of 24 weeks. SENSE (n=675) was primarily 
designed to collect safety data for up to 12 months on nalmefene, but after the 
study had started the protocol was amended to include efficacy analyses. 
SENSE had a follow-up period of 12 months. 
3.2 Psychosocial support (in the form of BRENDA), focusing on treatment 
adherence and reduction of alcohol consumption, was provided to all treatment 
groups in the 3 studies. The first part comprised a biopsychosocial evaluation, 
followed by sharing the results with the patient. The next stage involved 
expressing empathy for the patient and together identifying their needs, 
providing direct advice to the patient to meet those needs, assessing patient 
reaction to advice and adjusting the treatment plan as needed. All sessions were 
provided by trained professionals and were delivered at weekly intervals for the 
first 2 weeks and then monthly. Sessions lasted for 15–30 minutes except for 
the first longer session, which was 30–40 minutes. 
3.3 Alcohol dependence was diagnosed using the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV-TR). To be included in the studies, patients must 
have had 14 or fewer days of abstinence in the 28 days preceding the screening 
visit, and have an average daily alcohol consumption of medium risk or higher: 
equivalent to more than 40 g per day (equivalent to more than 5 units) for men 
and more than 20 g per day (equivalent to more than 2.5 units) for women. 
Patients had at least 6 heavy drinking days in the 28 days prior to enrolment. A 
heavy drinking day was defined, in line with the World Health Organization 
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classification of drinking risk levels, as alcohol consumption of more than 60 g 
per day (equivalent to more than 7.5 units) for men and more than 40 g per day 
(equivalent to more than 5 units) for women. People with severe medical 
comorbidities were excluded from all 3 studies, and those with severe 
psychiatric comorbidities were excluded from the 2 ESENSE trials. The 3 studies 
were conducted across different regions of Europe. In total, there were 156 
 sites; 5 sites in the UK were included in the SENSE trial. 
3.4 The ESENSE trials contained 4 study periods. The first was a 1–2 week 
screening period, after which all patients were randomised 1:1 to either the 
nalmefene plus BRENDA group or placebo plus BRENDA group for 24 weeks. 
Patients were then instructed to take 1 tablet (the maximum daily dose) on an 
'as-needed' basis, preferably 1–2 hours before they perceived a risk of drinking. 
If the patients started to drink without taking a tablet, they were advised to take 
a tablet as soon as possible. The patients who completed the 24-week trial 
entered a 4-week, double-blind, run-out period to evaluate any treatment 
discontinuation effects. Those who had been initially randomised to nalmefene 
were re-randomised to receive either nalmefene or placebo, and patients 
originally in the placebo group continued on placebo. A safety follow-up visit 
was scheduled for 4 weeks after completion of the run-out period or after 
withdrawal from the study. 
3.5 Similar to the ESENSE studies, the SENSE study also began with a 1–2 week 
screening period, after which patients were randomised 3:1 to receive 52 weeks 
of as-needed treatment with nalmefene plus BRENDA or placebo plus BRENDA. 
A safety follow-up period was scheduled for 4 weeks after completion of the 
study or after withdrawal from the study. 
3.6 The primary outcomes in ESENSE1 and ESENSE2 measured changes from 
baseline in the number of heavy drinking days per month and total alcohol 
consumption at month 6. The company highlighted that the primary end points 
of number of heavy drinking days and total alcohol consumption were in 
accordance with the recommendations in the European Medicines Agency 
guideline on the development of medicinal products for the treatment of alcohol 
dependence. Total alcohol consumption was defined as mean daily alcohol 
consumption in grams per day, over a month (28 days). Patients self-reported 
their daily alcohol consumption using the timeline follow-back method at 
monthly intervals. This provided retrospective estimates of the number of 
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standard drinks consumed each day in the previous month, which were 
subsequently converted into grams of alcohol per day. Secondary outcomes 
included the effect of nalmefene on: proportion of people whose alcohol 
dependence responded to treatment based on different drinking measures, 
alcohol dependence symptoms and clinical status, liver function and other 
clinical safety laboratory tests, pharmaco-economic outcomes, treatment 
withdrawal effects after 24 weeks, safety and tolerability of nalmefene and 
quality-of-life measures (SF-36 and EQ-5D). 
3.7 Similar to ESENSE1 and ESENSE2, the primary outcomes for the SENSE study 
were change from baseline in the number of heavy drinking days per month and 
total alcohol consumption at month 6. These outcomes were added as an 
amendment to the protocol while the study was ongoing. No protocol 
amendments were made to outcomes to assess the safety and tolerability of 
nalmefene. 
3.8 In ESENSE1 and ESENSE2, approximately 78% of all patients enrolled had a high 
or very high drinking risk level at baseline. In SENSE, 52% of the enrolled 
patients had a high or very high drinking risk level at baseline. In ESENSE1, 
ESENSE2 and SENSE, 74%, 57% and 52% respectively continued drinking at this 
level at randomisation. After an agreement with the Scientific Advisory Group 
to the European Medicines Agency, the company performed a post hoc analysis 
in the subgroup of patients in the 3 studies who had a high or very high drinking 
risk level both at baseline and at randomisation. The company stated that the 
Scientific Advisory Group recognised the validity of the post hoc subgroup 
analyses and that these analyses form the basis of the marketing authorisation 
for nalmefene. 
3.9 Results of the post hoc analyses in the licensed population (that is, people who 
had a high or very high drinking risk level at baseline and maintained such a level 
at randomisation) showed that there were greater reductions in the number of 
heavy drinking days and total alcohol consumption in patients treated with 
nalmefene plus BRENDA, than with placebo plus BRENDA. The treatment 
difference in the changes from baseline to 6 months in the number of heavy 
drinking days, using mixed model repeated measures analysis, was −3.7 days per 
month (95% confidence interval [CI] −5.9 to −1.5, p=0.001) in ESENSE1, and 
−2.7 days per month (95% CI −5.0 to −0.3, p=0.025) in ESENSE2. The treatment 
difference in the changes from baseline to 6 months in total alcohol 
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consumption was −18.3 g per day (95% CI −26.9 to −9.7, p<0.001) in ESENSE1, 
and −10.3 g per day (95% CI −20.2 to −0.5, p=0.040) in ESENSE2. In the SENSE 
study, the treatment difference in the changes from baseline to 6 months in the 
number of heavy drinking days was −2.6  days per month (95% CI −5.5 to 0.2, 
p=0.071) at 6 months, and −3.6 days per month (95% CI −6.5 to −0.7, p=0.016) 
at month 13. The difference in total alcohol consumption at month 6 was 
−15.3 g per day (95% CI −29.1 to −1.5, p=0.031) and at month 13 was −17.3 g 
per day (95% CI −30.9 to −3.8, p=0.013). 
3.10 The company did not perform a meta-analysis of the efficacy data for the 
ESENSE1, ESENSE2 and SENSE studies but pooled the primary outcomes, the 
change from baseline to month 6 in monthly heavy drinking days, and total 
alcohol consumption from ESENSE1 and ESENSE2. In the ESENSE1 and 
ESENSE2 studies there were 23 heavy drinking days per month at baseline in 
the nalmefene plus BRENDA group with a reduction to 10 heavy drinking days 
per month at month 6 (a reduction of 55%). In the placebo plus BRENDA group 
there were 22 heavy drinking days per month at baseline with a reduction to 
13 heavy drinking days per month at month 6 (a reduction of 42%). At 6 months 
the number of heavy drinking days had been reduced by 3.01 days per month 
(95% CI −4.36 to −1.66, p<0.0001) and total alcohol consumption had been 
reduced by 14.22 g per day (95% CI −19.96 to −8.47, p<0.0001). In the ESENSE1 
and ESENSE2 studies there was a total alcohol consumption of 107.7 g per day 
in the nalmefene plus BRENDA group, which reduced to 49.0 g per day at 
month 6 (a reduction of 61%). In the placebo plus BRENDA group there was a 
total alcohol consumption of 103.3 g per day, which reduced to 51.9 g per day at 
month 6 (a reduction of 50%). The odds ratio for the pooled response of drinking 
risk level for the ESENSE1 and ESENSE2 trials was 1.87 (95% CI 1.35 to 2.59, 
p<0.001). 
3.11 The company reported the results for a number of secondary outcomes in the 3 
nalmefene studies. Secondary outcomes included response at month 6 
(response of drinking risk level defined as a downward shift from baseline in 
drinking risk level by 2 risk categories). The odds ratio for nalmefene for 
response of drinking risk level was 2.15 (95% CI 1.38 to 3.36, p<0.001) in the 
ESENSE1 study and 1.59 (95% CI 0.98 to 2.59, p=0.062) in the ESENSE2 study. 
In ESENSE1 and ESENSE2, the EQ-5D health state and utility index score in the 
licensed population increased more from baseline to month 6 in the nalmefene 
plus BRENDA group than in the placebo plus BRENDA group. This was 
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statistically significantly in favour of nalmefene for the health state score in 
ESENSE1 only. Pooled analysis of the EQ-5D (a quality of life questionnaire) 
results in ESENSE1 and ESENSE2 in the licensed population produced a mean 
change from baseline, for the health state score and the utility index score, of 
3.46 points (p=0.0124) for the health state score and 0.03 points (p=0.0445) for 
the utility index score. The EQ-5D health state and utility index score in the 
licensed population increased more from baseline to month 6 in the nalmefene 
group than in the placebo group with a mean change in utility index score from 
baseline to month 6 of 0.03±0.02 (95% CI 0.00 to 0.06, p=0.0445) and a mean 
change in health state score from baseline to month 6 of 3.46±1.38 (95% CI 0.75 
to 6.17, p=0.0124). 
Nalmefene compared with naltrexone 
3.12 Because there were no direct head-to-head studies comparing nalmefene plus 
BRENDA with naltrexone (comparator) plus psychosocial intervention, the 
company investigated whether a network meta-analysis or indirect comparison 
could be conducted. The company carried out a systematic review to identify 
studies evaluating nalmefene and naltrexone for the reduction of alcohol 
consumption in people who were actively drinking and had alcohol dependence. 
The review identified 3 randomised controlled studies that compared oral 
naltrexone (50 mg per day) plus psychosocial intervention, with placebo plus 
psychosocial intervention in actively drinking adults with alcohol dependence. 
The company stated that all the studies had limitations in the data reported, 
meaning that an indirect comparison could not be performed. These differences 
included study design, inclusion and exclusion criteria, study objective and end 
points as well as a lack of reporting of data from the naltrexone studies. 
BRENDA (psychosocial support in ESENSE1, ESENSE2 and SENSE) compared 
with other types of psychological interventions 
3.13 To determine which types of psychosocial intervention should be included in the 
systematic review, the company carried out a survey of 20 primary care 
practices and experts and concluded that the following types of psychosocial 
intervention should be incorporated: cognitive behavioural therapies, 
behavioural therapies, social network and environment therapies, brief 
interventions and motivational enhancement therapy. 
3.14 The company carried out a literature search and identified 7 studies on 
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psychosocial intervention that met the inclusion criteria and which the company 
added to the 43 studies identified in the NICE guideline on alcohol-use 
disorders. The company did not carry out a meta-analysis of these studies (no 
explicit reasons were provided in the company's submission) but it did provide a 
summary of the absolute reductions in drinking that were provided in the 
psychosocial intervention trials. These trials showed that absolute reduction in 
total alcohol consumption from these studies ranged from 9.3–50.7 g per day, 
with a median value of 18.3 g per day (range of follow-up time: 6–12 months). 
For the absolute reduction in number of monthly heavy drinking days, the range 
was 1.3–19, with a median value of 5.7 days (range of follow-up time: 
3–12 months). In the nalmefene studies, the absolute reduction in total alcohol 
consumption in the nalmefene plus BRENDA group ranged from 58.3–70.4 g 
per day, whereas in the placebo plus BRENDA group, the absolute reduction 
ranged from 40.0–60.1 g per day. The absolute reduction in the number of 
monthly heavy drinking days in the nalmefene plus BRENDA group ranged from 
11.6–12.9 days, whereas in the placebo plus BRENDA group the absolute 
reduction ranged from 8.0–10.2 days (range of follow-up time: 6–12 months). 
3.15 The frequency of treatment-emergent adverse events was recorded for all 
3 nalmefene trials for both the total and licensed population. The percentage of 
adverse events was slightly higher in the licensed population than in the total 
population. The adverse events observed with the highest incidences in the 
nalmefene group as compared with the placebo group were nausea, dizziness, 
insomnia and headache. The incidence of nausea (22%) and dizziness (18%) 
were high in the first month of treatment but decreased to approximately 1–2% 
in subsequent months. Treatment-emergent psychiatric events that included 
confusion, abnormal thinking and hallucinations were approximately 3 times 
more common with nalmefene, with an incidence of 2.9%. 
Cost effectiveness 
3.16 The company developed a de novo analysis to estimate the cost effectiveness of 
as needed nalmefene plus psychosocial support compared with psychosocial 
support alone for treating alcohol dependence. The company used a Markov 
model, which consisted of a short-term model (1 year based on the nalmefene 
studies) with 1 month cycles, and a long-term model (up to 5 years using 
extrapolated trial results) with 1 year cycles. The model with 1 month cycles 
aimed to take account of treatment efficacy and patient adherence, observed 
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treatment discontinuation, incidence of alcohol-attributed harmful events and 
deaths. It also reduced the number of assumptions and uncertainties needed by 
the company. The 1 month cycle length was used to align with the patient 
follow-up in the nalmefene studies (number of heavy drinking days and total 
alcohol consumption over 28 days). Half-cycle correction was not incorporated 
because the company considered these to be negligible, because the initial 
cycles were 1 month long. The model was developed based on the nalmefene 
studies that used BRENDA as the psychosocial support. 
3.17 The population in the model consisted of a cohort with alcohol dependence and 
defined drinking levels according to the World Health Organization's definition 
of drinking risk levels (see table 1). In accordance with the pooled data from 
ESENSE1, ESENSE2 and the SENSE studies, the company assumed that on entry 
to the model, 57.5% of those patients who met the criteria specified in the 
marketing authorisation for nalmefene, would be in the very high risk drinking 
level and 42.5% would be in the high risk drinking level. 
Table 1 World Health Organization definition of drinking risk levels 
Drinking risk level (applies to a single day) Total consumption (g/day) 
Men Women 
Very high risk >100 >60 
High risk >60–100 >40–60 
Medium risk >40–60 >20–40 
Low risk 1–40 1–20 
Abstinent 0 0 
3.18 The short-term time horizon of 1 year contained 5 drinking level health states as 
shown in table 1. Patients entered the model in either the high or very high 
drinking level state in line with the marketing authorisation for nalmefene. After 
the first year, 3 yearly health states were considered: controlled drinking, 
medium risk drinking, and high or very high risk drinking. Patients in the 
controlled drinking health state were assumed to be of a low risk drinking level 
or abstinent after 12 months and therefore these patients stopped all 
treatments. 
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3.19 To account for the possibility that patients with controlled drinking may become 
heavy drinkers again, 19% were modelled to relapse at the end of the year and 
due to have a second round of treatment. Patients who relapsed returned to the 
same treatment in which they were initially successful in controlling their 
alcohol intake. The proportion of patients who relapsed was also distributed 
among the drinking levels in the same way as the initial patient cohort in the 
model. The same transition probabilities were also applied. It was assumed that 
treatment was effective in patients in the medium risk drinking level group after 
12 months, and patients continued on treatment but this only applied to 
approximately 10% of patients in the model. These patients could transition to 
either controlled drinking or high or very high risk drinking level, leading to a 
second-line treatment option. After 12 months, it was presumed that treatment 
was not effective in patients in the high or very high risk drinking group and 
their current treatment was stopped. They were modelled to change treatment 
strategy to an abstinence-orientated or second-line approach, which would 
include assisted alcohol withdrawal followed by acamprosate or oral naltrexone 
plus psychosocial intervention, to prevent relapse. 
3.20 Transition probabilities for patients changing drinking state in the first year 
were obtained from pooled data from the ESENSE1, ESENSE2 and SENSE 
studies. Transition probabilities for the subsequent years were obtained from 
different sources, depending on the drinking risk level. The abstinent or low 
drinking risk levels were based on data reported by Taylor et al. (1985), with the 
transition probabilities for those in the medium drinking risk level calculated 
from the last 6 months of the SENSE study. 
3.21 The risk of a patient experiencing a serious or temporary harmful event was 
related to their World Health Organization drinking risk level. The serious 
harmful events included by the company were based firstly on those events that 
were costly to the healthcare system and had a strong evidence base. The 
company also modelled temporary events using tunnel states including costs 
and quality-adjusted life year (QALY) decrements but no long-term effects were 
accounted for when the person survived the tunnel state. Temporary events 
comprised of lower respiratory tract infections, transport-related injuries and 
injuries not related to transport. Patients who experienced a serious event 
stayed in that state for the remaining duration of the model. Patients who 
experienced a temporary event stayed in a tunnel health state for 1 month 
before returning to the pre-tunnel health state. In a tunnel state, the proportion 
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of patients passing through the state (or event) acquired costs and an immediate 
decrement in utility, in addition to other costs (alcohol treatment costs) and 
utilities incurred by the drinking level health states. However, the state or event 
will not produce any long-term effects as long as the patient survives the tunnel 
state. 
3.22 To take account of the risks of crime in the first year of treatment, the company 
applied relative risks for each drinking risk level to an underlying general 
population value, which is assumed to be those patients that are abstinent. The 
company assumed a number of probabilities of committing crime based on 
gender in the first year. 
3.23 The company's model allowed patients to move from any health state to the 
death state over the time horizon. Patients could die either from 
alcohol-attributed harmful events or all-cause mortality. 
3.24 The model also incorporated risks of dropping out because of harmful events 
from nalmefene or other reasons. This was based on data from the 3 pooled 
nalmefene clinical trials in the model. An adverse event could cause the patient 
to change or stop their treatment, depending on the treatment and the source 
of the adverse event. If a patient dropped out because of nalmefene-related 
adverse events, they stayed in the nalmefene treatment arm but their treatment 
changed to psychosocial support only. Patients who changed treatment because 
of nalmefene-related adverse events transitioned to their corresponding 
drinking level for the psychosocial support treatment. For both the nalmefene 
plus psychosocial support treatment and the psychosocial support alone, 
patients who dropped out because of other reasons had their treatment 
changed to 'no treatment' and transitioned immediately to high or very high 
World Health Organization drinking risk level with the same distribution as at 
entry into the model. 
3.25 A number of cost parameters were used in the model, with the cost of a visit to 
the GP or expert care being the same for both nalmefene plus psychosocial 
support and psychosocial support alone. For both these groups, the proportion 
of patients receiving treatment at a GP practice and at expert level was set at 
75% and 25% respectively. 
3.26 In the model, the costs of second-line treatment with naltrexone or 
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acamprosate were taken from the NICE guideline on alcohol-use disorders. The 
second-line treatment for assisted withdrawal using naltrexone or acamprosate 
had several costs attached, depending on the location of treatment: home-based 
assisted withdrawal (£596), secondary care outpatient-assisted withdrawal 
(£606) or secondary care inpatient-assisted withdrawal (£4145). The company 
then used a weighted average of £1044 per patient having medically assisted 
withdrawal. The model also took into account societal costs related to both 
crime and productivity as specified in the remit to NICE from the Department of 
Health. The inclusion of a societal perspective was taken account of in scenario 
analyses and was not included in the company's base case. 
3.27 Utility weights were obtained from the EQ-5D questionnaire, used to assess 
patients' health-related quality of life in the 3 nalmefene trials. The EQ-5D data 
were used to model the effect of a reduction in alcohol consumption. The results 
from the 3 trials were pooled to estimate utility values for the 
cost-effectiveness model (see section 3.11 for results). 
3.28 The company's base-case results showed that nalmefene plus psychosocial 
support dominated psychosocial support alone (that is, it is more effective and 
less costly). The company carried out a number of sensitivity analyses. The 
parameters that had the most effect on the cost effectiveness results were the 
number of medical visits per month (for both treatments), the proportion of 
people having treatment following relapse, the utility values used and the cost 
of nalmefene. Nalmefene plus psychosocial support still dominated when all 
parameters were varied, except for when the number of medical visits per 
month was doubled. When applying the upper bound for this parameter, the 
incremental cost-effectiveness ratio (ICER) increased to £6274 per QALY 
gained. 
3.29 The company also tested 8 different scenarios observing the impact of varying 
the time horizon, perspective on cost, assuming nalmefene intake on every day 
that the patient was in the model, source of utility data used and removing the 
second-line treatment option (results in brackets after each scenario). 
• Scenario 1: Time horizon reduced to 1 year (ICER was £24,684 per QALY gained for 
nalmefene plus psychosocial support compared with psychosocial support). 
• Scenario 2: Societal perspective included (nalmefene plus psychosocial support 
continued to dominate psychosocial support). 
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• Scenario 3: Time horizon reduced to 1 year and societal perspective included 
(nalmefene plus psychosocial support continued to dominate psychosocial support). 
• Scenario 4: Nalmefene intake assumed to be every day rather than as needed (ICER 
was £289 per QALY gained for nalmefene plus psychosocial support compared with 
psychosocial support). 
• Scenario 5: No second-line treatment options are allowed (ICER was £5090 per QALY 
gained for nalmefene plus psychosocial support compared with psychosocial support). 
• Scenario 6: Using utility values from the STREAM study (nalmefene plus psychosocial 
support continued to dominate psychosocial support). 
• Scenario 7: A threshold analysis increasing the treatment effect of psychosocial 
support relative to nalmefene plus psychosocial support to identify the level of efficacy 
needed to have an ICER of £20,000 and of £30,000 per QALY gained. 
• Scenario 8: An assumption that psychosocial support was associated with zero costs 
(£8088 cost per QALY gained for nalmefene plus psychosocial support compared with 
psychosocial support). 
3.30 After a clarification request, the company corrected a minor error in the model 
and presented 2 further scenarios (termed scenarios 9 and 10 by the ERG). 
Scenario 9 provided an ICER for the use of psychosocial intervention as 
suggested by the NICE guideline on alcohol-use disorders, with 1 session of 
psychosocial intervention lasting 60 minutes per week for 12 weeks. 
Scenario 9A increased the costs of psychosocial support in the psychosocial 
support alone arm, whereas scenario 9B assumed the cost increase for 
psychosocial support applied to both nalmefene plus psychosocial support arm 
and psychosocial support alone arm. In both situations (9A and 9B), nalmefene 
plus psychosocial support dominated psychosocial support alone. Scenario 10 
assessed alternative assumptions for the treatment pathway of patients at a 
medium risk level after 12 months. Three scenarios were explored: the first 
assumed that patients relapse after 12 months to high or very high drinking risk 
level; the second assumed that treatment was effective and was modelled in line 
with other patients in whom treatment was effective; the third scenario 
assumed that treatment was not effective in patients in the nalmefene plus 
psychosocial support arm but that it was for patients in the psychosocial 
support alone arm. For the first 2 scenarios, nalmefene plus psychosocial 
support still dominated psychosocial support alone, whereas for the third 
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scenario the ICER was £6280 per QALY gained when comparing nalmefene plus 
psychosocial support with psychosocial support alone. 
Evidence Review Group's comments 
3.31 The ERG commented that the company had carried out a comprehensive 
systematic review and all relevant studies for nalmefene plus psychosocial 
support were included. It was unsure if all relevant naltrexone data had been 
included. The ERG also commented that the company's model was generally 
well constructed and had few errors. 
3.32 The ERG indicated that the post hoc subgroup analyses of patients who had high 
or very high drinking risk level in the 3 nalmefene studies may cause the efficacy 
and safety data to be less robust because they were not powered for this 
analysis. The robustness may also be affected by the high dropout rates in the 
nalmefene trials. The company carried out sensitivity analyses to account for 
the missing data but there were some inconsistencies as to whether statistical 
significance was achieved or not. The ERG also indicated that patient 
self-reporting of alcohol intake could bias the results. 
3.33 The ERG indicated that the uncertainties in the clinical evidence related to the 
types and frequencies of psychosocial intervention, along with its treatment 
duration and generalisability to England. Psychosocial support in the form of 
BRENDA was used in the nalmefene trials but was delivered at different 
intervals to the psychosocial intervention (including behavioural therapies, 
cognitive behavioural therapy and behavioural couples therapies) 
recommended in the NICE guideline on alcohol-use disorders. The ERG stated 
that the evaluation carried out in the model does not meet that specified in the 
final scope and that it was difficult to know how the results would apply to 
people receiving different forms and frequencies of psychosocial intervention. 
3.34 The ERG had concerns about the generalisability of the population in the 
3 nalmefene studies to clinical practice in England. People with severe 
psychiatric comorbidities were excluded from all 3 nalmefene trials, and those 
with severe medical comorbidities were excluded from the ESENSE trials. The 
company commented in its submission that many people with alcohol 
dependence also have diagnosed medical conditions and/or psychiatric 
comorbidities. Patients were also excluded from the nalmefene trials if they 
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were taking certain medication, such as drugs for angina, anticoagulants, 
anticonvulsants, insulin, sedatives and systemic steroids. The ERG stated that 
the safety and efficacy of nalmefene in people taking these drugs was therefore 
uncertain. Only a small number of trial patients were from the UK (SENSE trial 
only, 5 sites out of a total of 156) and the company did not provide any data on 
the variability of the outcomes for different European countries. The ERG 
stated that the generalisability of this data for England was unknown. 
3.35 The ERG noted that naltrexone was not formally modelled as a comparator in 
the economic analysis even though it was included in the final scope issued by 
NICE. The model assumed that if patients stopped nalmefene treatment 
because of adverse events, they would switch to psychosocial support alone, but 
it did not account for switching to naltrexone. The ERG commented that it was 
unsure whether this assumption could be favourable or unfavourable to 
nalmefene. 
3.36 The ERG stated that its clinical advisers did not agree with the assumption that 
people would remain on treatment (regardless of drinking level) for the full year. 
The ERG commented that its clinical advisers believed that GPs would not let 
patients drink at very high risk levels for more than 6 months without 
recommending intensification of psychosocial intervention and additional 
expert input, and that 3 months might be a more likely cut-off point. 
Evidence Review Group's exploratory analyses 
3.37 The ERG formulated 4 comparisons in its exploratory analysis (see table 2). 
Table 2 The 4 comparisons formulated by the Evidence Review Group 
Comparison Definition 
Comparison 1 The analysis of the cost effectiveness of adding nalmefene to a psychosocial 
intervention of lower intensity than recommended in the NICE guideline on 
alcohol-use disorders. 
Comparison 2 Threshold analyses that estimates the reduction in the benefit associated with 
nalmefene necessary to reach cost per quality-adjusted life years (QALYs) of 
£20,000 and £30,000. 
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Comparison 3 The company did not comment on the likely cost effectiveness of delayed 
initiation of nalmefene for people whose alcohol dependence did not respond to 
psychosocial intervention as recommended in the NICE guideline on alcohol-use 
disorders, compared with immediate initiation of nalmefene for all patients. 
Delayed use of nalmefene would be aligned with the recommendation for 
pharmacotherapy in the NICE guideline on alcohol-use disorders, although this 
guideline was written before nalmefene was licensed. 
Comparison 4 The company did not comment on the likely cost effectiveness of nalmefene use 
(delayed or immediate) with the use of off-label naltrexone, following informed 
consent being obtained, as recommended in the NICE guideline on alcohol-use 
disorders. 
3.38 For comparison 1, the ERG carried out a number of exploratory analyses 
including: 
• Analysis 1: Impact of patients withdrawing from nalmefene because of adverse events, 
also withdrawing from psychosocial support – 2 scenarios were run, the first assumed 
that all patients withdrawing from nalmefene also withdrew from psychosocial 
support, and the second assumed that 50% of the patients also withdrew from 
psychosocial support. 
• Analysis 2: 50% of patients received outpatient medically assisted withdrawal and 50% 
had this treatment at home. 
• Analysis 3: The costs for serious and temporary events were zero and the utility was 
the same as the very high risk level, although the ERG did not deem this plausible. 
• Analysis 4: The cost of an expert psychosocial support appointment was £119 rather 
than £94, according to more recent data. 
• Analysis 5: The utility for patients on nalmefene plus psychosocial support and for 
psychosocial support alone were equal in the first year, although the ERG did not deem 
this plausible. 
3.39 The ERG's base case included assumptions 1, 2 and 5, with the additional 
assumption that 50% of people withdrawing from nalmefene would also 
withdraw from psychosocial support treatment. In the ERG base case, 
nalmefene plus psychosocial support still dominated psychosocial support 
alone. The ERG carried out a second analysis using their base case assumption 
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but also presumed no second-line treatment options were allowed and the ICER 
was £5166 per QALY gained when comparing nalmefene plus psychosocial 
support with psychosocial support alone. Although the ERG was critical of the 
fact that the company did not conduct a half-cycle correction, the model was not 
adapted by the ERG to allow this for 2 reasons: the first was the time needed to 
carry out this adaptation and the second because after the first year (in which 
monthly cycles were used), there was no differential efficacy between the 
2 arms apart from people drinking at medium drink risk levels. Also, any 
potential inaccuracy was relatively small compared with the uncertainty 
explored in comparisons 2 and 3. 
3.40 For comparison 2, the ERG suggested that it was unlikely for people at medium 
risk drinking level to have treatment indefinitely and assumed in comparison 1 
that these people would relapse to high and very high risk levels. The ERG was 
unable to carry out a threshold analysis altering the variable treatment options 
because this part of the model was not functioning, and also given that the 
impact in the ICER was small, the ERG left the assumption as it was. The 
threshold analysis carried out by the company in scenario 7 was reassessed in 
the ERG's comparison 2 (with the exception that those at a medium risk drinking 
level were assumed to remain on treatment). The results produced by the ERG 
were similar to the company's results. If the efficacy of nalmefene and 
psychosocial support compared with psychosocial support alone were reduced 
by 62.8%, then the ICER would become £20,000 per QALY gained. The 
reduction would have to be 71.5% for the ICER to reach £30,000 per QALY 
gained. When additional factors accounting for the potential cost of crime and 
loss of productivity were considered, the efficacy of nalmefene and psychosocial 
support compared with psychosocial support alone would need to be reduced 
by 80.4% and 83.1% for the ICER to be £20,000 and £30,000 per QALY gained 
respectively. 
3.41 For comparison 3, the ERG highlighted that there were few data to assess the 
cost effectiveness of nalmefene with psychosocial intervention when using the 
psychosocial intervention as described in the NICE guideline on alcohol-use 
disorders. The time point at which psychosocial intervention alone was not 
successful was also unknown but the nalmefene trials indicated that when 
patients were treated with BRENDA alone, approximately 20% were either 
abstinent or of low risk drinking level at month 3. The ERG suggested a greater 
response may be seen with higher-intensity psychosocial intervention and that 
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the costs of nalmefene can be saved without incurring health losses particularly 
if nalmefene use was delayed. The ERG did caution that there would be 
uncertainty about the efficacy of nalmefene in patients whose alcohol 
dependence had not responded to psychosocial support alone. 
3.42 For comparison 4, again the ERG suggested there were few data available and 
therefore did not feel comfortable estimating an ICER for this comparison. 
3.43 Full details of all the evidence are available. 
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4 Consideration of the evidence 
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of 
nalmefene, having considered evidence on the nature of reducing alcohol consumption in people 
with alcohol dependence and the value placed on the benefits of nalmefene by people with the 
condition, those who represent them, and clinical experts. It also took into account the effective 
use of NHS resources. 
4.1 The Committee considered the clinical need for treatment in people with 
alcohol dependence and who have a high drinking risk level. It heard from a 
patient expert about the impact of alcohol dependency on both the patient and 
their family. The patient experts explained that the aim of treatment is to reduce 
the impact of symptoms on quality of life, including physical, mental and 
financial constraints for the patient and their family. The clinical experts stated 
that reducing alcohol intake also reduces the extent of liver disease in patients. 
The patient experts also explained that the availability of any extra 
interventions to treat alcohol dependency would be welcomed, because the 
currently available treatments are not always successful.The Committee 
acknowledged the demands that living with alcohol dependency can have on the 
patient and their family and accepted that an additional treatment option for 
these patients is important. 
4.2 The Committee discussed the current clinical management of alcohol 
consumption in people with alcohol dependency who have a high drinking risk 
level, without physical withdrawal symptoms and who do not require immediate 
detoxification, including the most appropriate comparator for nalmefene. The 
Committee was aware that the NICE guideline on alcohol-use disorders 
recommends that moderation of drinking, rather than abstinence from alcohol, 
may be appropriate for people with mild dependence without significant 
comorbidity and with adequate social support. It heard from the clinical experts 
that psychosocial intervention in the form of brief or extended brief 
interventions was the standard first-line treatment in England for these people. 
The Committee understood that although the NICE guideline on alcohol-use 
disorders recommends a specific intensity, duration and frequency of 
psychosocial intervention, the usual psychosocial intervention provided in 
clinical practice was brief or extended brief interventions. It noted that both the 
duration and frequency of these interventions were shorter than that 
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recommended in the guideline and that the provision of psychosocial 
interventions differs throughout England. The Committee was aware that 
naltrexone was also listed as a comparator in the final scope for this appraisal, 
despite it not having a marketing authorisation in the UK for the same indication 
as nalmefene, that is for the reduction of alcohol consumption rather than 
abstinence or relapse prevention. However, the clinical experts explained that 
naltrexone is used in practice to treat a different patient group than those 
included in the nalmefene trials, with abstinence as the treatment goal. The 
Committee noted that during consultation, some consultees indicated that 
naltrexone is sometimes used in practice to treat mild alcohol dependency 
because it is pharmacologically similar to nalmefene. The Committee heard 
from the clinical experts that nalmefene plus psychosocial support is an 
important addition to the treatment pathway because it is the first 
pharmacological intervention that is specifically for alcohol reduction rather 
than abstinence. The Committee concluded that psychosocial intervention in 
the form of brief or extended brief intervention is a valid comparator for 
nalmefene plus psychosocial support and the most appropriate comparator for 
this appraisal. 
4.3 The Committee considered how nalmefene will be prescribed in clinical 
practice, noting that the marketing authorisation states that 'nalmefene should 
only be prescribed in conjunction with continuous psychosocial support'. The 
Committee heard that in clinical practice, most patients with mild alcohol 
dependency (defined using an assessment tool such as the alcohol use disorders 
identification kit [AUDIT]) would be treated in the primary care setting with 
delivery of brief or extended brief interventions, and may not see a secondary 
care expert. However, during consultation, some consultees suggested that 
expert alcohol services in secondary care were still providing psychosocial 
interventions for patients who do not require pharmacological assistance. The 
patient experts explained that providing nalmefene treatment in primary care 
could reduce the stigma sometimes associated with expert treatment, and that 
families may also feel empowered to help people continue with treatment. The 
Committee was aware that for harmful drinkers and people with mild alcohol 
dependence, the NICE guideline on alcohol-use disorders recommends that 
psychosocial intervention (including behavioural therapies, cognitive 
behavioural therapy and behavioural couples therapies) should typically consist 
of 60 minute weekly sessions over a 12-week period, and be delivered by 
appropriately trained and competent staff. The Committee was also aware that 
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the psychosocial intervention in the guideline is of greater intensity than would 
be provided by brief or extended brief interventions. The Committee heard 
from the clinical experts that the current services available in England have 
difficulty providing the level of psychosocial interventions recommended in the 
NICE guideline on alcohol-use disorders. Other comments received during 
consultation suggested that GPs would need further training to provide 
psychosocial support to patients and that brief or extended brief intervention as 
provided by GPs, is not at the intensity of BRENDA used in the trials. The 
Committee noted the uncertainty and conflicting opinions among the 
stakeholders regarding the most appropriate setting for prescribing nalmefene 
in conjunction with psychosocial support. However, it was aware that making 
specific recommendations about the setting for prescribing nalmefene was 
outside the scope of a technology appraisal. 
Clinical effectiveness 
4.4 The Committee considered the evidence on the clinical effectiveness of 
nalmefene plus psychosocial support, noting that the evidence was derived from 
the ESENSE1, ESENSE 2 and SENSE studies. It discussed whether the 
population in the 3 studies reflects those seen in clinical practice in England, and 
whether it could allow clinicians to determine the population eligible for 
nalmefene. The Committee noted from the trials that patients must be 
diagnosed as having alcohol dependency using the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV-TR), with an average daily alcohol 
consumption classed as medium risk or higher (more than 40 g [5 units] per day 
for men and more than 20 g [2.5 units] per day for women) with at least 6 heavy 
drinking days (defined as more than 60 g per day for men and more than 40 g 
per day for women) in the last 28 days, and 14 or fewer abstinent days in the 
4 weeks before the screening visit. It heard from the clinical experts that the 
inclusion criteria reflected the definition in the NICE guideline on alcohol-use 
disorders for mild alcohol dependence and the World Health Organization's 
classification of drinking risk levels.The Committee noted that the 2 ESENSE 
studies excluded people with severe psychiatric conditions or severe medical 
comorbidities, but noted the company's consultation response explaining that at 
the UK sites of the SENSE trial, nalmefene was given to patients with stable 
psychiatric comorbidities and who were taking multiple medications. It also 
noted that none of the sites in the ESENSE trials was in the UK, and that only 
5 sites in the SENSE trial were UK-based. The Committee was aware that both 
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the company and the Evidence Review Group (ERG) had commented that many 
people who have alcohol dependence also have medical conditions or 
psychiatric conditions. The Committee was also aware that the clinical experts 
agreed with this view. The Committee concluded that the baseline 
characteristics of the populations in the 3 studies were not wholly generalisable 
to clinical practice in England, but provided sufficient evidence for clinicians to 
determine the appropriate patient population for treatment with nalmefene 
plus psychosocial support, with the psychosocial support focusing on treatment 
adherence and reducing alcohol consumption. 
4.5 The Committee discussed the psychosocial support used both in conjunction 
with and as a comparator to nalmefene in the ESENSE1, ESENSE2 and SENSE 
studies. It was aware that the psychosocial support provided in the studies was 
in the form of BRENDA (see section 3.1), which is not currently used in clinical 
practice in England, although it is used in clinical trials. The Committee 
considered if BRENDA, as administered in the clinical trials, is applicable to 
clinical practice in England. It was aware that the NICE guideline on alcohol-use 
disorders specifies the type and frequency of psychosocial intervention that 
should be offered to people with mild alcohol dependence who wish to reduce 
their alcohol consumption, and that both the intervention and comparator in the 
final scope issued by NICE specified psychological intervention 'as defined in 
NICE clinical guideline 115'. The Committee heard from the clinical experts that 
BRENDA was delivered at different intervals and intensity to both the 
psychosocial intervention as described in the NICE guideline on alcohol-use 
disorders and that used in clinical practice in England. However, it heard from 
the clinical experts that although BRENDA is not used in its entirety in clinical 
practice, most of the components within it are currently provided in the form of 
brief or extended brief interventions and could be administered by healthcare 
professionals. The Committee accepted that BRENDA, as described in the 
3 nalmefene studies, closely resembled current established practice. It 
concluded that the clinical effectiveness evidence based on the comparison with 
BRENDA was relevant to clinical practice in England. 
4.6 The Committee considered the clinical-effectiveness results of the 3 nalmefene 
studies. It agreed that it should only consider the post hoc subgroup analyses 
carried out on trial patients in the 3 nalmefene studies with a high or very high 
drinking risk level at baseline who maintained such a level at randomisation 
because these analyses formed the basis of the licensed population in the 
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marketing authorisation for nalmefene. The Committee was aware that the 
subgroup analyses had not been pre-specified but had been performed because 
18% (ESENSE1), 33% (ESENSE2) and 25% (SENSE) of patients reduced drinking 
between screening study visits and randomisation, therefore leaving little scope 
for additional improvement. The Committee noted the ERG's concerns that the 
subgroup efficacy data may be less robust because none of the studies were 
powered for this analysis and initial randomisation may have been lost with the 
high dropout rate possibly affecting the results. It was also aware that the 
Scientific Advisory Group to the European Medicines Agency recognised the 
validity of the subgroup analyses and that these analyses formed the basis of 
the licensed population in the marketing authorisation for nalmefene. The 
Committee accepted that the post hoc subgroup analyses were sufficiently 
robust to use in its decision-making. It noted that the results from the post hoc 
subgroup analyses suggested that people in the nalmefene plus BRENDA group 
had fewer heavy drinking days per month and total alcohol consumption per day 
compared with those who received placebo plus BRENDA. However, the 
Committee was concerned that the differences between the treatment groups 
were relatively small (13% in heavy drinking days and 11% in total alcohol 
consumption), suggesting that most of the treatment gain from nalmefene could 
be attributed to the psychosocial support (BRENDA). The Committee heard 
from the clinical experts that both the number of heavy drinking days and total 
alcohol consumption are clinically relevant outcome measures and that 
although the reduction in these outcomes appear modest, they are clinically 
significant. The Committee concluded that nalmefene plus BRENDA reduces 
the number of heavy drinking days and total alcohol consumption compared 
with BRENDA alone, although the exact magnitude of effect was uncertain 
because of the post hoc subgroup analyses and the trials were not powered for 
these analyses (see section 3.8). 
4.7 The Committee noted that there were no trials directly comparing nalmefene 
plus psychosocial support with naltrexone plus psychosocial intervention, and 
the company had not presented an indirect comparison of the 2 treatments. The 
Committee accepted the rationale provided by the company and that the ERG 
had agreed it would be inappropriate to carry out an indirect comparison given 
the limitations of the naltrexone studies identified by the company. The 
Committee was aware that naltrexone plus psychosocial intervention is 
recommended in the NICE guideline on alcohol-use disorders (although oral 
naltrexone does not have a UK marketing authorisation for the same indication 
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as nalmefene, that is for the reduction of alcohol consumption rather than 
abstinence or relapse prevention) for people whose alcohol dependence did not 
respond to psychosocial intervention, or those who have specifically requested 
a pharmacological intervention, and that it was included as a comparator in the 
final scope issued by NICE. The Committee agreed that the relative 
effectiveness of nalmefene plus psychosocial support and naltrexone plus 
psychosocial intervention was uncertain, mainly because of limitations in the 
available evidence base for naltrexone in people with mild alcohol dependence. 
The Committee noted that consultation comments from a professional group 
and patient and carer group suggested a comparison between naltrexone and 
nalmefene would be helpful, because some patients are being treated with 
naltrexone in a similar way to the nalmefene licence. It considered whether an 
indirect comparison should have been carried out (albeit an imperfect one) as it 
was included in the final scope issued by NICE. The Committee had heard from 
the clinical experts that naltrexone plus psychosocial intervention was not part 
of established practice for the reduction of alcohol consumption, and it agreed 
that naltrexone plus psychosocial intervention could not be considered an 
appropriate comparator. The Committee concluded that it would not consider 
further the comparison of nalmefene plus psychosocial support compared with 
naltrexone plus psychosocial intervention in its decision-making. 
4.8 The Committee considered the health-related quality of life benefits associated 
with nalmefene plus BRENDA. The Committee noted that the company had 
collected health-related quality of life data as measured by the EQ-5D and 
SF-36 in all 3 nalmefene trials. The Committee was aware that the reference 
case outlined in NICE's Guide to the methods of technology appraisal 2013 
states that EQ-5D is the preferred measure of health-related quality of life in 
adults and concluded that the utility data available from the EQ-5D was the 
most appropriate for its decision-making. The Committee noted that the results 
from the EQ-5D analyses (see section 3.11) suggested that nalmefene plus 
BRENDA improved a person's health-related quality of life compared with 
placebo plus BRENDA. The Committee was also aware that it had heard from 
the patient experts that health-related quality of life was important and any 
treatment that could have a positive impact on quality of life was considered 
valuable (see section 4.1). The Committee agreed that the EQ-5D data showed 
that nalmefene plus BRENDA improved health-related quality of life compared 
with placebo plus BRENDA. 
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4.9 The Committee considered the company's economic model and the review and 
exploratory sensitivity analyses performed by the ERG. It discussed the 
company's general approach to developing the nalmefene plus psychosocial 
support economic model. It noted that the ERG considered the company's 
model to be well structured with most of the assumptions being unfavourable to 
nalmefene. The ERG commented that the company had not included a half-cycle 
correction and that this was a limitation of the model. However, the ERG 
acknowledged that the impact of a half-cycle correction in the monthly time 
cycles was likely to be small. The Committee concluded that the outlined 
structure of the model adhered to the NICE reference case for economic 
analysis and was accepted for assessing the cost effectiveness of nalmefene plus 
psychosocial intervention. 
4.10 The Committee considered the company's cost-effectiveness analyses for 
comparing nalmefene plus psychosocial support with psychosocial support 
alone. It noted that the company had provided a base-case analysis in which the 
psychosocial support in both the intervention and comparator groups was 
BRENDA, which was an intervention of lower intensity than that recommended 
in the NICE guideline on alcohol-use disorders (see section 3.28). The 
Committee accepted the company's base-case incremental cost-effectiveness 
ratio (ICER) that nalmefene plus psychosocial support dominated psychosocial 
support alone. The Committee was aware of the ERG's comments that the 
evaluation carried out in the model does not meet the final scope issued by 
NICE because the scope stated psychosocial intervention as defined by the 
NICE guideline on alcohol-use disorders. The Committee noted that the ERG 
had formulated 4 comparisons testing the robustness of the cost effectiveness 
of nalmefene plus psychosocial intervention relevant to the decision problem 
defined in the scope, that is, psychosocial intervention as defined in the NICE 
guideline on alcohol-use disorders (see section 3.37). The Committee discussed 
which of the ERG's 4 comparisons were most appropriate for its 
decision-making. The Committee was aware of its decision to accept that brief 
or extended brief interventions as the appropriate comparator for nalmefene 
and that it was satisfied that the psychosocial support used in the nalmefene 
studies (BRENDA, as part of the intervention and the comparator) closely 
represented current clinical practice in England. The Committee therefore 
agreed that the ERG's comparison 1 (which corresponded with the company's 
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base-case analysis) was the most appropriate analysis. 
4.11 The Committee considered the ERG's exploratory amendments in 
comparison 1. It noted the amendments made by the ERG to the company's base 
case (see sections 3.38–3.39). The Committee noted that the changes did not 
include amending the company's assumption that people would remain on 
treatment (regardless of drinking risk level) for the full year. It discussed 
whether the company's assumption that patients would remain on treatment 
for 12 months regardless of drinking level and response was reasonable. The 
Committee heard from both the clinical experts and the ERG that it is unlikely 
that GPs would allow a patient to continue treatment and continue drinking at a 
high drinking risk level for up to 1 year. The Committee understood that the 
length of treatment time would be decided on an individual basis between the 
clinician and patient but that 12 months of treatment was possible. The 
Committee was aware that it was unclear to the ERG if such changes to the 
duration of treatment would be favourable or unfavourable to nalmefene plus 
psychosocial support. The ERG had commented that it was highly unlikely to 
change the cost-effectiveness results from comparison 1. The Committee 
considered the 7 exploratory analyses carried out by the ERG and the ERG's 
exploratory base case, which combined 4 of the ERG'S exploratory analyses: 
medium-risk drinkers relapsed to high or very high risk, all of the patients who 
withdrew for nalmefene-related responses also withdrew from psychosocial 
support, the average cost of medically assisted withdrawal was £645 per patient 
and that the cost of an expert psychosocial support appointment was £119. 
With these assumptions taken into account, the ERG's exploratory base case 
indicated that nalmefene plus psychosocial support still dominated psychosocial 
support alone (that is, was less expensive and more effective). The Committee 
also discussed that when the ERG presumed no second-line treatments were 
available, the incremental cost-effectiveness ratio (ICER) increased to £5100 
cost per quality-adjusted life year (QALY) gained for nalmefene plus 
psychosocial support compared with psychosocial support alone. It concluded 
that based on the analyses provided by the ERG the ICER would lie somewhere 
between nalmefene plus psychosocial support being dominant and £5100 per 
QALY gained compared with psychosocial support alone. 
4.12 The Committee also discussed whether any other factors should be taken into 
account when considering the cost effectiveness of nalmefene plus psychosocial 
support. It noted that adopting a wider perspective than the NHS and personal 
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social services, as included in the remit from the Department of Health, resulted 
in nalmefene plus psychosocial support still dominating psychosocial support 
alone. The Committee considered whether the utility values used in the 
economic model incorporated all the health-related quality-of-life benefits 
associated with a reduction in alcohol consumption. The Committee was aware 
that it had heard from patient experts that reducing alcohol consumption was of 
considerable importance to family members and carers (see section 4.1). The 
Committee agreed that the utility values used in the economic model may have 
underestimated the true benefit of nalmefene plus psychosocial support. 
Although aware of the uncertainty about whether the results from the 
3 nalmefene clinical studies are generalisable to patients seen in practice in 
England (see section 4.4) and the uncertainty associated with the post hoc 
subgroup analyses (see section 4.6), taking into account the wider societal 
perspective and the possible underestimation of the utility values, the 
Committee agreed that the most plausible ICER was likely to be lower than 
£5100 per QALY gained. The Committee therefore concluded that nalmefene 
given in conjunction with psychosocial support was a cost-effective use of NHS 
resources compared with psychosocial support alone for treating people with 
alcohol dependence who have a high drinking risk level, without physical 
withdrawal symptoms and who do not require immediate detoxification. 
4.13 The Committee discussed the issue of adherence to nalmefene treatment in 
clinical practice, given that it should only be prescribed in conjunction with 
psychosocial support focusing on treatment adherence and reducing alcohol 
consumption. The Committee was aware that the summary of product 
characteristics for nalmefene indicates that physicians should continue to 
assess the patient's progress in reducing alcohol consumption and treatment 
adherence and that physicians must take this into consideration when 
prescribing nalmefene plus psychosocial support. The clinical experts 
commented that although some patients in clinical practice may be less likely to 
adhere to treatment because of the need to document their drinking level, or to 
attend their scheduled psychosocial intervention sessions, there are many who 
would be sufficiently motivated to adhere to all aspects of the treatment. The 
Committee heard from the clinical experts that patients taking nalmefene 
would usually be given information to ensure that they understand why 
adherence to treatment (in terms of when they take their medication, recording 
of alcohol consumption and attendance at psychosocial support sessions) is 
important. The Committee concluded that treatment adherence for both 
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nalmefene and psychosocial support is an important consideration for 
physicians when prescribing treatment. 
4.14 The Committee noted the concerns raised during both its meetings and the 
consultation regarding difficulties that may be encountered complying with the 
implementation period in which to provide funding for nalmefene. It was aware 
of the requirement for the relevant health bodies (clinical commissioning 
groups, NHS England and local authorities) to provide funding to ensure the 
technology is available within 3 months, from the date the recommendation is 
published by NICE. The Committee noted that the provision of psychosocial 
intervention differs throughout England, and the licence for nalmefene 
mandates that treatment should be given in combination with psychosocial 
support. The Committee highlighted that it would be reasonable for NICE to 
reflect on whether the standard 3 month implementation period is appropriate. 
4.15 The Committee noted the potential equality issue raised by a patient expert and 
a Committee member in the meeting that families may be stigmatised for having 
a family member with alcohol dependence. It also noted the equality issue 
raised in a clinical expert statement, suggesting that there could be issues with 
consent of treatment in certain populations in terms of cognitive decline and 
learning disability. The Committee considered that healthcare professionals 
should be mindful of the need to ensure equality of access to treatment for 
patients with disabilities. The Committee concluded that its recommendation 
on the use of nalmefene plus psychosocial support does not have a particular 
impact on any group with a protected characteristic in the equality legislation 
and that there was no need to alter or add to its recommendations. 
Summary of Appraisal Committee's key conclusions 
TA325 Appraisal title: Nalmefene for reducing alcohol consumption in 
people with alcohol dependence 
Section 
Key conclusions 
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Nalmefene is recommended within its marketing authorisation, as an option for 
reducing alcohol consumption, for people with alcohol dependence: 
• who have a high drinking risk level (defined as alcohol consumption of more than 
60 g per day for men and more than 40 g per day for women, according to the World 
Health Organization's drinking risk levels) without physical withdrawal symptoms 
and 
• who do not require immediate detoxification. 
The marketing authorisation states that nalmefene should: 
• only be prescribed in conjunction with continuous psychosocial support focused on 
treatment adherence and reducing alcohol consumption and 
• be initiated only in patients who continue to have a high drinking risk level 2 weeks 
after initial assessment. 
1.1 
The Committee understood that although the NICE guideline on alcohol-use disorders 
recommends a specific intensity, duration and frequency of psychosocial intervention, 
the usual psychosocial intervention provided in clinical practice was brief or extended 
brief interventions and that both the duration and frequency of these interventions 
were shorter than that recommended in the NICE guideline on alcohol-use 
disorders.The Committee concluded that psychosocial intervention in the form of brief 
or extended brief intervention is a valid comparator for nalmefene plus psychosocial 
support and the most appropriate comparator for this appraisal. 
4.2 
The Committee noted the uncertainty and conflicting opinions among the stakeholders 
regarding the most appropriate setting for prescribing nalmefene plus psychosocial 
intervention. However the Committee was aware that making specific 
recommendations about the setting for prescribing nalmefene was outside the scope 
of a technology appraisal. 
4.3 
The Committee was aware that the psychosocial support provided in the studies was in 
the form of BRENDA. It heard from experts that although BRENDA is not used in its 
entirety in clinical practice, most the components within it are currently provided in 
the form of brief or extended brief interventions, and could be administered by health 
professionals. The Committee accepted that BRENDA closely resembled current 
established practice and the clinical effectiveness evidence based on the comparison 
with BRENDA was relevant to clinical practice. 
4.5 
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The Committee concluded that nalmefene plus BRENDA reduces the number of heavy 
drinking days and total alcohol consumption compared with BRENDA alone, although 
the exact magnitude of effect was uncertain because of the post hoc subgroup analyses 
and the trials were not powered for these analyses. 
4.6 
The Committee agreed that the most plausible incremental cost effectiveness ratio 
(ICER) was likely to be lower than £5100 per quality adjusted life year (QALY) gained, 
and therefore concluded that nalmefene plus psychosocial support was a 
cost-effective use of NHS resources compared with psychosocial support alone. 
4.12 
Current practice 
Clinical need of 
patients, including 
the availability of 
alternative 
treatments 
The Committee heard from patient experts that alcohol 
dependency can have a substantial negative effect on quality of 
life, including physical, mental and financial constraints for the 




of the technology 
How innovative is 
the technology in 
its potential to 





The Committee heard from the clinical experts that nalmefene 
plus psychosocial support is an important addition to the 
treatment pathway as it is the first pharmacological intervention 
that is specifically for alcohol reduction rather than abstinence. 
4.2 
What is the 
position of the 
treatment in the 
pathway of care 
for the condition? 
The Committee heard from the clinical experts that nalmefene 
plus psychosocial support is an important addition to the 
treatment pathway as it is the first pharmacological intervention 
that is specifically for alcohol reduction rather than abstinence. 
4.2 
Adverse reactions The summary of product characteristics lists the following adverse 
reactions for nalmefene: nausea, dizziness, insomnia and 
headaches. For full details of adverse reactions and 
contraindications, see the summary of product characteristics. 
2.3 
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Evidence for clinical effectiveness 
Availability, 
nature and quality 
of evidence 
There were 3 randomised controlled trials (ESENSE1, ESENSE2 
and SENSE) in adults with alcohol dependence, comparing 18 mg 
nalmefene (on an as-needed basis) plus psychosocial support with 
placebo plus psychosocial support. Psychosocial support provided 
in the studies was in the form of BRENDA. 
The Committee noted that there were no trials directly comparing 
nalmefene plus psychosocial support with naltrexone plus 
psychosocial intervention, and the company had not presented an 





practice in the 
NHS 
The Committee heard from clinical experts that that psychosocial 
intervention (brief or extended brief intervention) provided in the 
primary care setting, was first-line treatment in England for people 
with alcohol dependency who have a high or very high drinking risk 
level without physical withdrawal symptoms and who do not 
require immediate detoxification. 
The Committee was aware that the NICE guideline on alcohol-use 
disorders recommends that psychosocial intervention should 
typically consist of weekly sessions of 60 minute duration over a 
12 week period but the current services available in England have 
difficulty providing this level of treatment. 
The Committee was also aware that the NICE guideline on 
alcohol-use disorders recommends that pharmacological 
interventions (such as naltrexone) are considered for people with 
mild alcohol dependence, only in those for whom psychosocial 
intervention alone has not helped or if people have specifically 
requested it. The clinical expert explained that naltrexone would 
be used in practice to treat a different patient group than those 
included in the nalmefene trials, with abstinence as the treatment 
goal. 
4.2, 4.3 
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generated by the 
evidence 
The Committee noted that the 2 ESENSE studies excluded people 
with severe psychiatric conditions and patients with severe 
medical comorbidities but took on board the company's 
consultation response detailing that at the UK sites in the SENSE 
trial, nalmefene was provided to patients with stable psychiatric 
co-morbidity and who were taking multiple medications. It also 
noted that none of the sites in the ESENSE trials were in the UK 
and only 5 sites in the SENSE trial were UK based. The Committee 
concluded that the baseline characteristics of the populations in 
the 3 studies were not wholly generalisable to clinical practice in 
England, but provided sufficient evidence to allow clinicians to 
determine the patient population for treatment with nalmefene 
plus psychosocial support. 
The Committee concluded that nalmefene plus BRENDA reduces 
the number of heavy drinking days and total alcohol consumption 
compared with BRENDA alone, although the exact magnitude of 
effect was uncertain because of the post hoc subgroup analyses 
and the trials were not powered for these analyses. 
The Committee was aware that it had heard from the clinical 
experts that naltrexone plus psychosocial intervention was not 
part of established practice for the reduction of alcohol 
consumption and agreed that naltrexone plus psychosocial 
intervention was not an appropriate comparator. The Committee 
concluded that it would not consider further the comparison of 
nalmefene plus psychosocial support compared with naltrexone 
plus psychosocial intervention in its decision-making. 
4.4, 
4.6, 4.7 
Are there any 
clinically relevant 
subgroups for 




The Committee considered that it should only consider the post 
hoc subgroup analyses in the marketing authorisation. No further 
subgroups were considered by the Committee. 
4.6 
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Estimate of the 





The Committee noted that the results from the post hoc subgroup 
analyses suggested that people in the nalmefene plus BRENDA 
group had fewer heavy drinking days per month and total alcohol 
consumption per day compared with those who received placebo 
plus BRENDA. 
4.6 




Having heard from the clinical experts that naltrexone plus 
psychosocial intervention was not part of established practice for 
the reduction of alcohol consumption, the Committee concluded 
that it would not consider further the comparison of nalmefene 
plus psychosocial support compared with naltrexone plus 
psychosocial intervention in its decision-making. 
The ERG considered the company's model to be well structured 
with most of the assumptions being unfavourable to nalmefene but 
commented that the company had not included a half-cycle 
correction and that this was a limitation of the model. 
The Committee concluded that the outlined structure of the model 
adhered to the NICE reference case for economic analysis and was 







inputs in the 
economic model 
The Committee discussed whether the company's assumption that 
patients would remain on treatment for 12 months regardless of 
drinking level and response was reasonable. Both the clinical 
experts and the ERG suggested it unlikely that GPs would allow a 
patient to continue treatment and continue drinking at a high 
drinking risk level for up to 1 year. The Committee was aware that 
it was unclear to the ERG if such changes to the duration of 
treatment would be favourable or unfavourable to nalmefene plus 
psychosocial support. 
4.11 
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were not included 
in the economic 
model, and how 
have they been 
considered? 
The Committee considered whether the utility values used in the 
economic model incorporated all the health-related quality of life 
benefits associated with a reduction in alcohol consumption. The 
Committee agreed that the utility values used in the economic 
model may have underestimated the true benefit of nalmefene 
plus psychosocial support because it did not take into account 
health-related quality of life of family and carers. 
4.12 
Are there specific 
groups of people 




Not applicable to this appraisal. - 
What are the key 
drivers of cost 
effectiveness? 
The Committee considered the ERG's exploratory amendments in 
comparison 1 and noted that the length of time for which people 
were treated with nalmefene was unlikely to affect the ICER. The 
Committee considered the 7 exploratory analyses carried out by 
the ERG and the ERG's exploratory base case, which combined 4 of 
the ERG'S exploratory analyses: medium-risk drinkers relapsed to 
high or very high risk, all of the patients who withdrew for 
nalmefene-related responses also withdrew from psychosocial 
support, the average cost of medically assisted withdrawal was 
£645 per patient and that the cost of an expert psychosocial 
support appointment was £119 and concluded the ICER was 
unlikely to be affected. 
4.11 
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estimate (given as 
an ICER) 
The Committee agreed that the most plausible ICER was likely to 
be lower than £5100 per QALY gained. The Committee therefore 
concluded that nalmefene plus psychosocial support was a 
cost-effective use of NHS resources compared with psychosocial 
support alone for treating people with alcohol dependence who 
have a high drinking risk level, without physical withdrawal 
symptoms and who do not require immediate detoxification. 
4.12 
Additional factors taken into account 
Patient access 
schemes (PPRS) 
Not applicable to this appraisal. - 
End-of-life 
considerations 
Not applicable to this appraisal. - 
Equalities 
considerations 
and social value 
judgements 
The Committee considered that healthcare professionals should 
be mindful of the need to ensure equality of access to treatment 
for patients with disabilities (in terms of issues with consent of 
treatment in certain populations, for example cognitive decline 
and learning disability). The Committee concluded that its 
recommendation on the use of nalmefene plus psychosocial 
support does not have a particular impact on any group with a 
protected characteristic in the equality legislation and that there 
was no need to alter or add to its recommendations. 
4.15 
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5.1 Section 7(6) of the National Institute for Health and Care Excellence 
(Constitution and Functions) and the Health and Social Care Information Centre 
(Functions) Regulations 2013 requires clinical commissioning groups, NHS 
England and, with respect to their public health functions, local authorities to 
comply with the recommendations in this appraisal within 3 months of its date 
of publication. 
5.2 When NICE recommends a treatment 'as an option', the relevant health bodies 
(clinical commissioning groups, NHS England and local authorities) must make 
sure it is available within the period set out in the paragraph above. This means 
that, if a patient has alcohol dependence and the doctor responsible for their 
care thinks that nalmefene is the right treatment, it should be available for use, 
in line with NICE's recommendations. 
5.3 NICE has developed tools to help organisations put this guidance into practice 
(listed below). 
• Adoption support resource 
• Costing template and report to estimate the national and local savings and costs 
associated with implementation. 
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6 Review of guidance 
6.1 The guidance on this technology will be considered for review 3 years after 
publication of the guidance. The Guidance Executive will decide whether the 
technology should be reviewed based on information gathered by NICE, and in 
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7 Appraisal Committee members, guideline 
representatives and NICE project team 
Appraisal Committee members 
The Appraisal Committees are standing advisory committees of NICE. Members are appointed for 
a 3 year term. A list of the Committee members who took part in the discussions for this appraisal 
appears below. There are 4 Appraisal Committees, each with a chair and vice chair. Each Appraisal 
Committee meets once a month, except in December when there are no meetings. Each Committee 
considers its own list of technologies, and ongoing topics are not moved between Committees. 
Committee members are asked to declare any interests in the technology to be appraised. If it is 
considered there is a conflict of interest, the member is excluded from participating further in that 
appraisal. 
The minutes of each Appraisal Committee meeting, which include the names of the members who 
attended and their declarations of interests, are posted on the NICE website. 
Professor Gary McVeigh (Chair) 
Professor of Cardiovascular Medicine, Queen's University Belfast and Consultant Physician, 
Belfast City Hospital 
Dr Lindsay Smith (Vice Chair) 
General Practitioner, West Coker Surgery, Somerset 
Dr Andrew Black 
General Practitioner, Mortimer Medical Practice, Herefordshire 
Professor David Bowen 
Consultant Haematologist, Leeds Teaching Hospitals NHS Trust 
Dr Matthew Bradley 
Therapy Area Leader, Value Evidence and Outcomes (Global), GlaxoSmithKline 
Miss Tracey Cole 
Lay Member 
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Professor Peter Crome 
Honorary Professor, Department of Primary Care and Population Health, UCL 
Professor Simon Dixon 
Professor of Health Economics, University of Sheffield 
Mrs Susan Dutton 
Senior Medical Statistician, Oxford Clinical Trials Research Unit 
Dr Alexander Dyker 
Consultant Physician, Wolfson Unit of Clinical Pharmacology, University of Newcastle 
Mr Christopher Earl 
Surgical Care Practitioner, Wessex Neurological Centre at Southampton University Hospital 
Mrs Gillian Ells 
Prescribing Advisor – Commissioning, NHS Hastings and Rother and NHS East Sussex Downs and 
Weald 
Professor Paula Ghaneh 
Professor and Honorary Consultant Surgeon, University of Liverpool 
Professor Carol Haigh 
Professor in Nursing, Manchester Metropolitan University 
Dr Alan Haycox 
Reader in Health Economics, University of Liverpool 
Professor John Henderson 
Professor of Paediatric Respiratory Medicine, University of Bristol and Bristol Royal Hospital for 
Children 
Dr Paul Hepple 
General Practitioner, Muirhouse Medical Group 
Professor Steven Julious 
Professor of Medical Statistics, University of Sheffield 
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Dr Tim Kinnaird 
Lead Interventional Cardiologist, University Hospital of Wales, Cardiff 
Ms Emily Lam 
Lay member 
Dr Paul Miller 
Director, Payer Evidence, AstraZeneca 
Dr Malcolm Oswald 
Lay member 
Professor Femi Oyebode 
Professor of Psychiatry and Consultant Psychiatrist, The National Centre for Mental Health 
Dr John Radford 
Director of Public Health, Rotherham Primary Care Trust and Metropolitan Borough Council 
Dr Murray Smith 
Associate Professor in Social Research in Medicines and Health, University of Nottingham 
Ms Pamela Rees 
Lay member 
Mr Cliff Snelling 
Lay member 
Professor Carolyn Young 
Consultant neurologist, Walton Centre for Neurology and Neurosurgery 
NICE project team 
Each technology appraisal is assigned to a team consisting of 1 or more health technology analysts 
(who act as technical leads for the appraisal), a technical adviser and a project manager. 
Dr Caroline Hall 
Technical Lead 
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8 Sources of evidence considered by the 
Committee 
A. The Evidence Review Group (ERG) report for this appraisal was prepared by the School of Health 
and Related Research: 
• Stevenson M, Pandor A, Stevens J, Rawdin A, Wong R, Morgan MY, Rice P, Thompson J. 
Nalmefene for reducing alcohol consumption in people with alcohol dependence: A Single 
Technology Appraisal. School of Health and Related Research (ScHARR), 2014. 
B. The following organisations accepted the invitation to participate in this appraisal as consultees 
and commentators. They were invited to comment on the draft scope, the ERG report and the 
appraisal consultation document (ACD). Organisations listed in I were also invited to make written 
submissions. Organisations listed in II and III had the opportunity to give their expert views. 




II. Professional/expert and patient/carer groups: 
• ADFAM 
• Alcohol Concern 
• British Liver Trust 
• Lifeline Project 
• British Association for Psychopharmacology 
• National Substance Misuse Non-Medical Prescribing Forum 
• Royal College of General Practitioners 
• Royal College of Nursing 
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• Royal College of Pathologists 
• Royal College of Physicians 
• Royal College of Psychiatrists 
III. Other consultees: 
• Department of Health 
• NHS England 
• NHS Stafford and Surrounds CCG 
• NHS Warrington CCG 
• Welsh Government 
IV. Commentator organisations (did not provide written evidence and without the right of appeal): 
• Association of Directors of Public Health 
• Department of Health, Social Services and Public Safety for Northern Ireland 
• Healthcare Improvement Scotland 
• Medicines and Healthcare products Regulatory Agency 
• Social Care Institute for Excellence 
• Bristol-Myers Squibb Pharmaceuticals 
• Institute of Alcohol Study 
• School of Health and Related Research 
• National Institute for Health Research Health Technology Assessment Programme 
C. The following individuals were selected from clinical expert and patient expert nominations from 
the consultees and commentators. They gave their expert personal view on nalmefene by attending 
the initial Committee discussion and providing written evidence to the Committee. They were also 
invited to comment on the ACD. 
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• Dr Chris Daly, Lead Consultant Addiction Psychiatrist, nominated by the Royal College of 
Psychiatrists – clinical expert 
• Simon Greasley, Specialist Nurse Practitioner, nominated by the Royal College of Nursing – 
clinical expert 
• Andrew Langford, nominated by British Liver Trust – patient expert 
• Oliver Standing, nominated by ADFAM– patient expert 
E. Representatives from the following company/sponsor attended Committee meetings. They 
contributed only when asked by the Committee chair to clarify specific issues and comment on 
factual accuracy. 
• Lundbeck 
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About this guidance 
NICE technology appraisal guidance is about the use of new and existing medicines and treatments 
in the NHS. 
This guidance was developed using the NICE single technology appraisal process. 
It has been incorporated into the NICE pathway on alcohol-use disorders in the interventions for 
harmful drinking and alcohol dependence path along with other related guidance and products. 
We have produced information for the public explaining this guidance. Tools to help you put the 
guidance into practice and information about the evidence it is based on are also available. 
NICE produces guidance, standards and information on commissioning and providing high-quality 
healthcare, social care, and public health services. We have agreements to provide certain NICE 
services to Wales, Scotland and Northern Ireland. Decisions on how NICE guidance and other 
products apply in those countries are made by ministers in the Welsh government, Scottish 
government, and Northern Ireland Executive. NICE guidance or other products may include 
references to organisations or people responsible for commissioning or providing care that may be 
relevant only to England. 
Your responsibility 
This guidance represents the views of NICE and was arrived at after careful consideration of the 
evidence available. Healthcare professionals are expected to take it fully into account when 
exercising their clinical judgement. However, the guidance does not override the individual 
responsibility of healthcare professionals to make decisions appropriate to the circumstances of 
the individual patient, in consultation with the patient and/or guardian or carer. 
Implementation of this guidance is the responsibility of local commissioners and/or providers. 
Commissioners and providers are reminded that it is their responsibility to implement the 
guidance, in their local context, in light of their duties to have due regard to the need to eliminate 
unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this 
guidance should be interpreted in a way that would be inconsistent with compliance with those 
duties. 
Copyright 
© National Institute for Health and Care Excellence 2014. All rights reserved. NICE copyright 
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material can be downloaded for private research and study, and may be reproduced for educational 
and not-for-profit purposes. No reproduction by or for commercial organisations, or for 
commercial purposes, is allowed without the written permission of NICE. 
ISBN 978-1-4731-0849-3 
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